Skip to main content

Advertisement

SpringerLink
Log in

Upgrade Rate and Long-term Outcomes of Lobular Neoplasia

  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Lobular neoplasia is a risk factor for breast cancer development, but its management remains controversial as upgrade rates differ depending on the subtype. This review of the literature aims to identify upgrade rates of lobular neoplasia, including their variants, discuss predictors of upgrade to malignancy, and provide information on long-term outcomes.

Recent Findings

Upgrade rates for atypical lobular hyperplasia and classic lobular carcinoma in situ are lower than non-classic lobular carcinoma in situ. Recent studies have focused on determining predictors of upgrade to malignancy with variable findings.

Summary

Upgrade rates for atypical lobular hyperplasia and classic lobular carcinoma in situ with concordant imaging-pathology remain low allowing for a surveillance approach. More studies on predictors of malignancy are needed to allow better counseling on management options for patients with these high-risk lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Neoplastic Diseases: a treatise on tumours. By James Ewing, A.M., M.D., Sc.D., Professor of Pathology at Cornell University Medical College, N.Y.; Pathologist to the Memorial Hospital. 3rd ed. Royal 8vo. Pp. 1127, with 546 illustrations. 1928. Philadelphia and London: W. B. Saunders Co. Ltd. 63s. net, Br J Surg. Volume 16, Issue 61, July 1928. p. 174–5, https://doi.org/10.1002/bjs.1800166126.

  2. Foote FW, Stewart FW. Lobular carcinoma in situ: A rare form of mammary cancer. Am J Pathol [Internet]. 1941 [cited 2023 Jun 24];17:234–7. Available from: https://pubmed.ncbi.nlm.nih.gov/19970575/.

  3. Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, et al. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med [Internet]. 2014 [cited 2023 Jun 25];3:492–9. Available from: https://pubmed.ncbi.nlm.nih.gov/24639339/.

  4. Brem RF, Lechner MC, Jackman RJ, Rapelyea JA, Evans WP, Philpotts LE, Hargreaves J, Wasden S. Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. AJR Am J Roentgenol. 2008 Mar;190(3):637-41. https://doi.org/10.2214/AJR.07.2768.

  5. Mahoney MC, Robinson-Smith TM, Shaughnessy EA. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up. AJR Am J Roentgenol [Internet]. 2006 [cited 2023 Aug 8];187:949–54. Available from: https://pubmed.ncbi.nlm.nih.gov/16985141/.

  6. Lunt L, Coogan A, Perez CB. Lobular Neoplasia. Surg Clin North Am [Internet]. 2022 [cited 2023 Jun 22];102:947–63. Available from: https://pubmed.ncbi.nlm.nih.gov/36335930/.

  7. Schnitt SJ, Brogi E, Chen YY, King TA, Lakhani SR. American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. Ann Diagn Pathol [Internet]. 2020 [cited 2023 Jun 25];45:151481. Available from: /pmc/articles/PMC7401835/.

  8. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy--clinical significance. Cancer [Internet]. 2004 [cited 2023 Aug 8];101:242–50. Available from: https://pubmed.ncbi.nlm.nih.gov/15241819/.

  9. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology [Internet]. 2001 [cited 2023 Aug 8];218:503–9. Available from: https://pubmed.ncbi.nlm.nih.gov/11161169/.

  10. Calle C, Kuba MG, Brogi E. Non-invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas. Breast J [Internet]. 2020 [cited 2023 Jun 22];26:1148–55. Available from: https://pubmed.ncbi.nlm.nih.gov/32500575/.

  11. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69.

    Article  CAS  PubMed  Google Scholar 

  12. Bonnett M, Wallis T, Rossmann M, Pernick NL, Bouwman D, Carolin KA, et al. Histopathologic Analysis of Atypical Lesions in Image-Guided Core Breast Biopsies. Mod Pathol 2003 162 [Internet]. 2003 [cited 2023 Aug 10];16:154–60. Available from: https://www.nature.com/articles/3880733.

  13. Foster MC, Helvie MA, Gregory NE, Rebner M, Nees A V., Paramagul C. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology [Internet]. 2004 [cited 2023 Aug 10];231:813–9. Available from: https://pubmed.ncbi.nlm.nih.gov/15105449/.

  14. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol [Internet]. 2005 [cited 2023 Aug 10];29:534–43. Available from: https://pubmed.ncbi.nlm.nih.gov/15767810/.

  15. Cangiarella J, Guth A, Axelrod D, Darvishian F, Singh B, Simsir A, et al. Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy?: a report of 38 cases and review of the literature. Arch Pathol Lab Med [Internet]. 2008 [cited 2023 Aug 10];132:979–83. Available from: https://pubmed.ncbi.nlm.nih.gov/18517282/.

  16. Hwang H, Barke LD, Mendelson EB, Susnik B. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol [Internet]. 2008 [cited 2023 Aug 10];21:1208–16. Available from: https://pubmed.ncbi.nlm.nih.gov/18660792/.

  17. Nagi CS, O’Donnell JE, Tismenetsky M, Bleiweiss IJ, Jaffer SM. Lobular neoplasia on core needle biopsy does not require excision. Cancer [Internet]. 2008 [cited 2023 Aug 10];112:2152–8. https://doi.org/10.1002/cncr.23415

  18. Lewis JL, Lee DY, Tartter PI. The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol [Internet]. 2012 [cited 2023 Aug 10];19:4124–8. Available from: https://pubmed.ncbi.nlm.nih.gov/22847126/.

  19. Niell B, Specht M, Gerade B, Rafferty E. Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol [Internet]. 2012 [cited 2023 Aug 10];199:929–35. Available from: https://pubmed.ncbi.nlm.nih.gov/22997389/.

  20. Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol [Internet]. 2012 [cited 2023 Aug 10];19:914–21. Available from: https://pubmed.ncbi.nlm.nih.gov/21861212/.

  21. Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, DePeri ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol [Internet]. 2012 [cited 2023 Aug 10];19:3131–8. Available from: https://pubmed.ncbi.nlm.nih.gov/22847124/.

  22. Zhao C, Desouki MM, Florea A, Mohammed K, Li X, Dabbs D. Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. Am J Clin Pathol [Internet]. 2012 [cited 2023 Aug 10];138:72–8. Available from: https://pubmed.ncbi.nlm.nih.gov/22706860/.

  23. Atkins KA, Cohen MA, Nicholson B, Rao S. Atypical Lobular Hyperplasia and Lobular Carcinoma in Situ at Core Breast Biopsy: Use of Careful Radiologic-Pathologic Correlation to Recommend Excision or Observation. [Internet]. 2013 [cited 2023 Aug 10];269:340–7. https://doi.org/10.1148/radiol.13121730.

  24. Chaudhary S, Lawrence L, McGinty G, Kostroff K, Bhuiya T. Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy. Mod Pathol [Internet]. 2013 [cited 2023 Jul 10];26:762–71. Available from: https://pubmed.ncbi.nlm.nih.gov/23307062/.

  25. Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer [Internet]. 2013 [cited 2023 Aug 10];119:1073–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23132235/.

  26. Shehata MN, Rahbar H, Flanagan MR, Kilgore MR, Lee CI, Ryser MD, et al. Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. J Am Coll Radiol. 2020;17:1207–19. This paper is the only meta-analysis reviewing upgrade rate of lobular neoplasia.

  27. Sapino A, Marchiò C, Kulka J. “Borderline” epithelial lesions of the breast: what have we learned in the past three decades? Pathologica [Internet]. 2021 [cited 2023 Aug 10];113:354. Available from: /pmc/articles/PMC8720406/.

  28. Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, et al. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol [Internet]. 2016 [cited 2023 Jul 10];23:722–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26542585/. This was a multi-institution prospective trial assessing the upgrade rate of LN diagnosed on core biopsy.

  29. Maxwell AJ, Clements K, Dodwell DJ, Evans AJ, Francis A, Hussain M, et al. The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. Breast [Internet]. 2016 [cited 2023 Aug 8];27:109–15. Available from: https://pubmed.ncbi.nlm.nih.gov/27060553/.

  30. Holbrook AI, Hanley K, Jeffers C, Kang J, Cohen MA. Triaging Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Percutaneous Core Biopsy to Surgery or Observation: Assiduous Radiologic-Pathologic Correlation Works, Quantitating Extent of Disease Does Not. Arch Pathol Lab Med [Internet]. 2019 [cited 2023 Jul 9];143:621–7. Available from: https://pubmed.ncbi.nlm.nih.gov/30576240/.

  31. Lee J, Ku GY, Lee H, Park HS, Ku JS, Kim JY, et al. Lobular Carcinoma In Situ during Preoperative Biopsy and the Rate of Upgrade. Cancer Res Treat. 2022;54:1074–80.

    Article  PubMed  Google Scholar 

  32. Donaldson AR, McCarthy C, Goraya S, Pederson HJ, Sturgis CD, Grobmyer SR, et al. Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy. Cancer [Internet]. 2018 [cited 2023 Aug 15];124:459–65. Available from: https://pubmed.ncbi.nlm.nih.gov/29023647/.

  33. Jani C, Lotz M, Keates S, Gupta Y, Walker A, Al Omari O, Parvez A, Patel D, Gnata M, Perry J, Khorashadi L, Weissmann L, Pories SE. Management of Lobular Neoplasia Diagnosed by Core Biopsy. Breast J. 2023 Apr 18;2023:8185446. https://doi.org/10.1155/2023/8185446

  34. Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S, Conant EF, et al. NCCN Guidelines Version 1.2023 Breast Cancer Screening and Diagnosis Continue NCCN Guidelines Panel Disclosures. 2023 [cited 2023 Jun 25]; Available from: https://www.nccn.org/home/member.

  35. Consensus Guideline on Concordance Assessment of Image-Guided Breast ..., www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf. Accessed 17 Jul 2023 

  36. Pride RM, Jimenez RE, Hoskin TL, Degnim AC, Hieken TJ. Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery [Internet]. 2021 [cited 2023 Jul 10];169:644–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32861439/.

  37. Elfgen C, Tausch C, Rodewald AK, Güth U, Rageth C, Bjelic-Radisic V, et al. Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast. Breast Care (Basel) [Internet]. 2022 [cited 2023 Jun 22];17:121–9. Available from: https://pubmed.ncbi.nlm.nih.gov/35702498/.

  38. El Khoury M, Sanchez LM, Lalonde L, Trop I, David J, Mesurolle B. Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy? Br J Radiol [Internet]. 2017 [cited 2023 Jun 25];90. Available from: /pmc/articles/PMC5605065/.

  39. Crary IL, Parker EU, Lowry KP, Patwardhan PP, Soong TR, Javid SH, et al. Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma. Ann Surg Oncol. 2022;29:6350–8.

    Article  PubMed  Google Scholar 

  40. Khoury T, Kumar PR, Li Z, Karabakhtsian RG, Sanati S, Chen X, et al. Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions. Mod Pathol [Internet]. 2016 [cited 2023 Jul 9];29:25–33. Available from: www.modernpathology.org.

  41. Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, DePeri ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol [Internet]. 2012 [cited 2023 Jul 10];19:3131–8. Available from: https://pubmed.ncbi.nlm.nih.gov/22847124/.

  42. Muller KE, Roberts E, Zhao L, Jorns JM. Isolated Atypical Lobular Hyperplasia Diagnosed on Breast Biopsy: Low Upgrade Rate on Subsequent Excision With Long-Term Follow-up. Arch Pathol Lab Med [Internet]. 2018 [cited 2023 Jul 10];142:391–5. Available from: https://pubmed.ncbi.nlm.nih.gov/29160721/.

  43. Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S. Supplemental Breast MR Imaging Screening of Women with Average Risk of Breast Cancer. Radiology [Internet]. 2017 [cited 2023 Oct 9];283:361–70. Available from: https://pubmed.ncbi.nlm.nih.gov/28221097/.

  44. Amitai Y, Menes TS, Scaranelo A, Fleming R, Kulkarni S, Ghai S, et al. Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided biopsy: can we estimate upgrade on surgical pathology? Breast Cancer Res Treat [Internet]. 2020 [cited 2023 Jul 9];184:881–90. https://doi.org/10.1007/s10549-020-05893-y.

  45. Nakhlis F, Harrison BT, King TA. Non-classic LCIS versus classic LCIS versus atypical hyperplasia: Should management be the same? Curr Surg Reports [Internet]. 2018 [cited 2023 Aug 27];6:1–11. https://doi.org/10.1007/s40137-018-0201-1.

  46. Lewin AA, Mercado CL. Atypical Ductal Hyperplasia and Lobular Neoplasia: Update and Easing of Guidelines. AJR Am J Roentgenol [Internet]. 2020 [cited 2023 Jun 22];214:265–75. Available from: https://pubmed.ncbi.nlm.nih.gov/31825261/.

  47. Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol [Internet]. 2001 [cited 2023 Aug 28];176:1255–9. Available from: https://pubmed.ncbi.nlm.nih.gov/11312190/

  48. Lavoué V, Graesslin O, Classe JM, Fondrinier E, Angibeau H, Levêque J. Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow-up surgical excision. Breast [Internet]. 2007 [cited 2023 Aug 28];16:533–9. Available from: https://pubmed.ncbi.nlm.nih.gov/17629481/.

  49. Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol [Internet]. 2008 [cited 2023 Aug 28];32:1721–6. Available from: https://pubmed.ncbi.nlm.nih.gov/18769331/.

  50. Carder PJ, Shaaban A, Alizadeh Y, Kumarasuwamy V, Liston JC, Sharma N. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology [Internet]. 2010 [cited 2023 Aug 28];57:472–8. Available from: https://pubmed.ncbi.nlm.nih.gov/20727019/.

  51. Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med [Internet]. 2010 [cited 2023 Aug 28];134:1024–8. Available from: https://pubmed.ncbi.nlm.nih.gov/20586632/.

  52. Stefano M, Carla BA, Giancarlo P, Codrina MO, Patrick M, Simona M, et al. Underestimation rate of lobular intraepithelial neoplasia in vacuum-assisted breast biopsy. Eur Radiol [Internet]. 2014 [cited 2023 Aug 28];24:1651–8. Available from: https://pubmed.ncbi.nlm.nih.gov/24744196/.

  53. Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH. Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management. Ann Surg Oncol [Internet]. 2015 [cited 2023 Aug 28];22:4263–9. Available from: https://pubmed.ncbi.nlm.nih.gov/25893410/.

  54. Savage JL, Jeffries DO, Noroozian M, Sabel MS, Jorns JM, Helvie MA. Pleomorphic Lobular Carcinoma In Situ: Imaging Features, Upgrade Rate, and Clinical Outcomes. AJR Am J Roentgenol [Internet]. 2018 [cited 2023 Jun 25];211:462–7. Available from: https://pubmed.ncbi.nlm.nih.gov/29894223/.

  55. Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, et al. Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Ann Surg Oncol [Internet]. 2019 [cited 2023 Jul 10];26:55–61. https://doi.org/10.1245/s10434-018-6937-0. This is one of the largest retrospective trial evaluation upgrade rate for patients diagnosed with NC-LCIS.

  56. Shamir ER, Chen YY, Chu T, Pekmezci M, Rabban JT, Krings G. Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma From a Single Academic Center. Am J Surg Pathol [Internet]. 2019 [cited 2023 Jun 25];43:399–408. Available from: https://pubmed.ncbi.nlm.nih.gov/30489319/.

  57. Foschini MP, Miglio R, Fiore R, Baldovini C, Castellano I, Callagy G, et al. Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature. Eur J Surg Oncol [Internet]. 2019 [cited 2023 Jul 3];45:2279–86. Available from: https://pubmed.ncbi.nlm.nih.gov/31301938/.

  58. Desai AA, Jimenez RE, Hoskin TL, Day CN, Boughey JC, Hieken TJ. Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Ann Surg Oncol [Internet]. 2018 [cited 2023 Aug 16];25:3064–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29947004/.

  59. Guo T, Wang Y, Shapiro N, Fineberg S. Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision. Clin Breast Cancer [Internet]. 2018 [cited 2023 Aug 12];18:e449–54. Available from: https://pubmed.ncbi.nlm.nih.gov/29102711/.

  60. Masannat YA, Husain E, Roylance R, Heys SD, Carder PJ, Ali H, et al. Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. Breast [Internet]. 2018 [cited 2023 Aug 16];38:120–4. Available from: https://pubmed.ncbi.nlm.nih.gov/29310036/.

  61. Foschini MP, Miglio R, Fiore R, Baldovini C, Castellano I, Callagy G, et al. Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature. Eur J Surg Oncol [Internet]. 2019 [cited 2023 Jun 25];45:2279–86. Available from: https://pubmed.ncbi.nlm.nih.gov/31301938/.

  62. Hoffman DI, Zhang PJ, Tchou J. Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution’s experience. Surg Oncol [Internet]. 2019 [cited 2023 Aug 27];28:190–4. Available from: https://pubmed.ncbi.nlm.nih.gov/30851899/.

  63. Schmidt H, Arditi B, Wooster M, Weltz C, Margolies L, Bleiweiss I, et al. Observation versus excision of lobular neoplasia on core needle biopsy of the breast. Breast Cancer Res Treat [Internet]. 2018 [cited 2023 Jun 22];168:649–54. Available from: https://docs.google.com/document/d/1EBm69lw7IBult2aOtgRz3VTYhoKgB8CFlMqyJrYYN1o/edit?usp=drive_web&ouid=102092556504539843754&usp=embed_facebook.

  64. Genco IS, Tugertimur B, Chang Q, Cassell L, Hajiyeva S. Outcomes of classic lobular neoplasia diagnosed on breast core needle biopsy: a retrospective multi-center study. Virchows Arch [Internet]. 2020 [cited 2023 Jun 22];476:209–17. Available from: https://pubmed.ncbi.nlm.nih.gov/31776645/.

  65. Karimi Z, Phillips J, Brook A, Baker G, Guzman Y, Mehta TS. Upgrade Rates of Pure, Radiology-Pathology Concordant Lobular Neoplasia Diagnosed on Breast Core Needle Biopsy: Is Surgical Excision Warranted? Acad Radiol. 2022;29:1029–38.

    Article  PubMed  Google Scholar 

  66. King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: A 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33:3945–52.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol [Internet]. 2017 [cited 2023 Aug 28];24:2509–17. Available from: https://pubmed.ncbi.nlm.nih.gov/28455673/.

  68. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol [Internet]. 2007 [cited 2023 Aug 28];25:2671–7. Available from: https://pubmed.ncbi.nlm.nih.gov/17563394/.

  69. Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, et al. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer [Internet]. 2016 [cited 2023 Aug 28];122:2971–8. Available from: https://pubmed.ncbi.nlm.nih.gov/27352219/.

  70. Bodian CA, Perzin KH, Lattes R. Lobular Neoplasia Long Term Risk of Breast Cancer and Relation to Other Factors. [cited 2023 Aug 28]; Available from: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/.

  71. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: Analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23:5534–41.

    Article  PubMed  Google Scholar 

  72. Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S, Conant EF, et al. NCCN Guidelines Version 1.2023 Breast Cancer Screening and Diagnosis Continue NCCN Guidelines Panel Disclosures. 2023 [cited 2023 Aug 28]; Available from: https://www.nccn.org/home/member.

  73. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2019 [cited 2023 Sep 17];30:1194–220. Available from: https://pubmed.ncbi.nlm.nih.gov/31161190/.

  74. Rageth CJ, O’Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat [Internet]. 2019 [cited 2023 Sep 17];174:279. Available from: /pmc/articles/PMC6538569/.

  75. Metovic, J., Abate, S.O., Borella, F. et al. The lobular neoplasia enigma: management and prognosis in a long follow-up case series. World J Surg Onc 19, 80 2021. https://doi.org/10.1186/s12957-021-02182-w

  76. Laws A, Katlin F, Nakhlis F, Chikarmane SA, Schnitt SJ, King TA. Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. Ann Surg Oncol [Internet]. 2022 [cited 2023 Jul 9];29:1660–7. Available from: https://pubmed.ncbi.nlm.nih.gov/34554341/.

  77. Matar R, Sevilimedu V, Park A, King TA, Pilewskie M. Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. Ann Surg Oncol [Internet]. 2022 [cited 2023 Jun 22];29:1670–9. Available from: https://pubmed.ncbi.nlm.nih.gov/34671879/.

  78. King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol [Internet]. 2015 [cited 2023 Aug 8];33:3945–52. Available from: www.jco.

  79. Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by plomorphic lobular carcinoma in situ. Arch Pathol Lab Med [Internet]. 2011 [cited 2023 Aug 28];135:737–43. Available from: https://pubmed.ncbi.nlm.nih.gov/21631266/.

  80. Fasola CE, Chen JJ, Jensen KC, Allison KH, Horst KC. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J [Internet]. 2018 [cited 2023 Aug 16];24:66–9. Available from: https://pubmed.ncbi.nlm.nih.gov/28929550/.

  81. Fisher B, Costantino JP, Lawrence Wickerham D, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Wolmark, and other National Surgical Adjuvant Breast and Bowel Project Investigators. [cited 2023 Jul 9]; Available from: https://academic.oup.com/jnci/article/90/18/1371/897928.

  82. Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EMH, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat [Internet]. 2012 [cited 2023 Jul 9];136:627–33. Available from: https://pubmed.ncbi.nlm.nih.gov/23117858/.

  83. Crew KD. Addressing Barriers to Uptake of Breast Cancer Chemoprevention for Patients and Providers. Am Soc Clin Oncol Educ Book 35, e50–e58(2015). https://doi.org/10.14694/EdBook_AM.2015.35.e50

  84. Ropka ME, Keim J, Philbrick JT. Patient Decisions about Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis. J Clin Oncol. 2010;28:3090–5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Orlando Health Cancer Institute, Orlando Health, 1400 S Orange Ave, Orlando, FL, 32806, USA

    Sara Ardila, Taylor Maramara & Danielle Henry

  2. Department of Solid Tumor, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA

    Annabel Chen

  3. Department of Breast Surgery, Overlake Cancer Center, Overlake Medical Center, 1135 116th Ave NE, Suite 200, Bellevue, WA, 98004, USA

    April Phantana-angkool

Authors
  1. Sara Ardila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annabel Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taylor Maramara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Danielle Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. April Phantana-angkool
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SA and AP wrote and revised the main manuscript text and table. DH, AC, and TM contributed significantly with drafting of the manuscript. All authors reviewed the manuscript.

Corresponding author

Correspondence to April Phantana-angkool.

Ethics declarations

Competing interests

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ardila, S., Chen, A., Maramara, T. et al. Upgrade Rate and Long-term Outcomes of Lobular Neoplasia. Curr Breast Cancer Rep 16, 11–19 (2024). https://doi.org/10.1007/s12609-024-00520-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-024-00520-x

Keywords

Search

Navigation